Interesting read., page-7

Hey @Lefevre I just looked at AVH announcement (briefly). Does that mean they will get a fast-tracked path to FDA approval because the FDA said the application provides "significant, clinically meaningful advantages".

If so... what is the likelihood that RAP would follow a similar path, so instead of getting (potential) FDA approval in DEC 2016 it could be a lot quicker? Just your opinion? Surely RAP provides "significant, clinically meaningful advantages"!
Thanks
Investo.